THE SHUKRA PHARMACEUTICALS LIMITED HAS BEEN AUTHORISED BY WOCKHARDT LIMITED, ON A PAN INDIA BASIS TO REPRESENT, DISTRIBUTE AND MANAGE ITS PRODUCTS ACROSS ALL ESIC/ESIS HOAPITALS ACROSS ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shukra Pharmaceuticals has been authorized by Wockhardt Limited to distribute and manage its products across all ESIC/ESIS hospitals and Defence/AFMSD hospitals in India on a non-exclusive basis. The authorization was received on September 9, 2025 and is valid until March 2026. Under this arrangement, Shukra can quote products, collect orders, raise invoices and collect payments directly on behalf of Wockhardt. Key products include EMROK (Levonadifloxacin) and MIQNAF (Nafithromycin), which are breakthrough antibiotics for critical infections. The company says this tie-up will strengthen its presence in institutional and government healthcare networks and improve revenue visibility.
Positive for shareholders — this is a significant institutional distribution win with a marquee global pharma partner that could boost revenue and operational footprint, though the deal is short-term (valid only till March 2026) and non-exclusive, limiting long-term visibility.